Bone-specific response according to MDA criteria predicts immunotherapy efficacy among advanced non-small cell lung cancer (NSCLC) patients.

De Giglio, Andrea; Deiana, Chiara; Di Federico, Alessandro

De Giglio, Andrea; Deiana, Chiara; Di Federico, Alessandro.

Affiliation

De Giglio A; Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Via Giuseppe Massarenti, 9, 40138, Bologna, Italy. dr.degiglio@gmail.com.
Deiana C; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. dr.degiglio@gmail.com.
Di Federico A; Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Via Giuseppe Massarenti, 9, 40138, Bologna, Italy.

J Cancer Res Clin Oncol ; 149(5): 1835-1847, 2023 May.

Article in En | MEDLINE | ID: mdl-35750899

Subject(s)

Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Humans; Carcinoma, Non-Small-Cell Lung/pathology; Lung Neoplasms/pathology; Retrospective Studies; Treatment Outcome; Immunotherapy/methods

Key words

Bone metastasis; Immunotherapy; MDA criteria; Non-small cell lung cancer; RECIST criteria

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Lung Neoplasms Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: J Cancer Res Clin Oncol Year: 2023 Type: Article Affiliation country: Italy

Fulltext

XML

PubMed Links

Search on Google